Search
Ixabepilone
go.drugbank.com/drugs/DB04845ApprovedInvestigationalIxabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug.
SC12267
go.drugbank.com/drugs/DB05125InvestigationalSC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis.
Teduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalThe significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.
Protirelin
go.drugbank.com/drugs/DB09421ApprovedAlthough not currently available in any FDA-approved product, protirelin is a component of the TRH Test where it is used to test the response of the anterior pituitary gland in conditions such as secondary
Grapiprant
go.drugbank.com/drugs/DB12836InvestigationalVet approvedGrapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. … [L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836]
Casimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigationalA related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by shortened and partially functional dystrophin protein production.
Aminosalicylic acid
go.drugbank.com/drugs/DB00233ApprovedInvestigationalAn antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.
Dextrothyroxine
go.drugbank.com/drugs/DB00509ApprovedWithdrawnThe major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin. Thyroxine is released from thyroglobul...
Oxycodegol
go.drugbank.com/drugs/DB14146InvestigationalLoxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263].